Literature DB >> 9223663

Suppression of autocrine cell proliferation and tumorigenesis of human melanoma cells and fibroblast growth factor transformed fibroblasts by a kinase-deficient FGF receptor 1: evidence for the involvement of Src-family kinases.

A Yayon1, Y S Ma, M Safran, M Klagsbrun, R Halaban.   

Abstract

Basic Fibroblast Growth Factor (bFGF/FGF2) is thought to play a decisive role in malignant progression. Aberrant expression of bFGF causes constitutive autocrine activation of its cognate receptor and autonomous growth of human melanoma cells or bFGF transformed fibroblasts in culture. It remains to be determined, however, whether the endogenous bFGF confers growth advantage to tumors and what are the downstream targets of the activated FGF receptor critical for its transforming capacity. We therefore transfected metastatic melanoma cells and bFGF transformed mouse fibroblasts with a dominant-negative mutant of the murine FGF receptor 1 (fgfr1/flg), comprising the extracellular and transmembrane domains but lacking the intracellular kinase domain (dnflg). Reverse transcriptase-PCR, 125I-bFGF binding and affinity labeling analyses show that the truncated receptor is targeted to the membrane and is expressed at much higher levels than the endogenous receptor in all of the selected clones. Expression of the dnflg dramatically reduces the basal as well as bFGF induced growth of these cells in vitro and also suppresses their tumorigenic potential in nude mice. The expression of the dnflg does not significantly alter the general level of tyrosyl-phosphorylated proteins in the trunsduced melanoma cells. Rather, a major downstream affected target is a Src-family kinase, whose activity, determined by an in vitro immune kinase assay, is stimulated in normal melanocytes by exogenous bFGF, and is markedly reduced in the dnflg-expressing melanoma cells. The present study demonstrates that direct interference with the activity of FGF receptors has a deleterious effect on cell proliferation and survival in vitro and in vivo leading to the suppression of melanoma tumor progression possibly through the inactivation of a Src-family kinase.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9223663     DOI: 10.1038/sj.onc.1201159

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.

Authors:  Thomas Metzner; Alexandra Bedeir; Gerlinde Held; Barbara Peter-Vörösmarty; Sara Ghassemi; Christine Heinzle; Sabine Spiegl-Kreinecker; Brigitte Marian; Klaus Holzmann; Bettina Grasl-Kraupp; Christine Pirker; Michael Micksche; Walter Berger; Petra Heffeter; Michael Grusch
Journal:  J Invest Dermatol       Date:  2011-07-14       Impact factor: 8.551

2.  Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.

Authors:  Tamás Garay; Eszter Molnár; Éva Juhász; Viktória László; Tamás Barbai; Judit Dobos; Karin Schelch; Christine Pirker; Michael Grusch; Walter Berger; József Tímár; Balázs Hegedűs
Journal:  Pathol Oncol Res       Date:  2015-03-09       Impact factor: 3.201

3.  A phase 2 trial of dasatinib in advanced melanoma.

Authors:  Harriet M Kluger; Arkadiuz Z Dudek; Carrie McCann; Jean Ritacco; Nadine Southard; Lucia B Jilaveanu; Annette Molinaro; Mario Sznol
Journal:  Cancer       Date:  2010-11-29       Impact factor: 6.860

4.  Ligand activation of alternatively spliced fibroblast growth factor receptor-1 modulates pancreatic adenocarcinoma cell malignancy.

Authors:  Selwyn M Vickers; Zhi-Qiang Huang; LeeAnn MacMillan-Crow; Jessica S Greendorfer; John A Thompson
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

5.  Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice.

Authors:  R Dono; G Texido; R Dussel; H Ehmke; R Zeller
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

Review 6.  Malignant melanoma in the 21st century: the emerging molecular landscape.

Authors:  Aleksandar Sekulic; Paul Haluska; Arlo J Miller; Josep Genebriera De Lamo; Samuel Ejadi; Jose S Pulido; Diva R Salomao; Erik C Thorland; Richard G Vile; David L Swanson; Barbara A Pockaj; Susan D Laman; Mark R Pittelkow; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2008-07       Impact factor: 7.616

7.  A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours.

Authors:  D S Boss; H Glen; J H Beijnen; M Keesen; R Morrison; B Tait; W Copalu; A Mazur; J Wanders; J P O'Brien; J H M Schellens; T R J Evans
Journal:  Br J Cancer       Date:  2012-04-19       Impact factor: 7.640

8.  FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients.

Authors:  S Streit; D S Mestel; M Schmidt; A Ullrich; C Berking
Journal:  Br J Cancer       Date:  2006-05-23       Impact factor: 7.640

Review 9.  Fibroblast Growth Factor Receptor Signaling in Skin Cancers.

Authors:  Malgorzata Czyz
Journal:  Cells       Date:  2019-06-04       Impact factor: 6.600

10.  Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel.

Authors:  Lucia B Jilaveanu; Fengmin Zhao; Christopher R Zito; John M Kirkwood; Katherine L Nathanson; Kurt D'Andrea; Melissa Wilson; David L Rimm; Keith T Flaherty; Sandra J Lee; Harriet M Kluger
Journal:  PLoS One       Date:  2013-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.